Skip to main content
Caplight Logo









AnaCardio

AnaCardio

Private
StockholmHealthcare & Life Scienceshttps://anacardio.com/

Last Round

Series A

Extension

Jan 9, 2025

Est. Valuation

$1.71M

Total Funding Raised

$34.24M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AnaCardio is a clinical-stage biopharmaceutical company that develops novel drugs to treat heart failure.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

heart failureHFrEFbiopharmaceuticalsmall molecule drugcardiac contractilityclinical trialsdrug developmentbiotech startupheart failure treatmentcardiovascular medicinedrug discoveryclinical researchpharma pipelinepreclinical pharmacology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AnaCardio Comparables

Compare AnaCardio with similar companies based on industry and business-model similarity.

AnaCardio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zensun (Shanghai) Sci & Tech Co., Ltd.
78%
Cardurion Pharmaceuticals
77%
Seismic Pharmaceutical Holdings
75%

AnaCardio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 9, 2025
Series ASep 8, 2022
VC RoundFeb 3, 2022
SeedJun 17, 2021

Key People

Founding team and executive leadership

Philipp Mathieu

Chief Financial Officer

Executive Team

Johan Sjödahl

Chief Operating Officer

Executive Team

AnaCardio Investors

Notable investors and investment history

AnaCardio investors
InvestorRounds
3B FUTURE Health FundSeries A
IndustrifondenSeries A Extension, VC Round, Series A
Novo HoldingsSeries A Extension
Karolinska Development ABSeries A, VC Round, Seed
Pureos BioventuresSeries A Extension
Flerie ABSeries A Extension, Series A
Sound BioventuresSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 32% MoM.

  • May 15, 2026

    Monthly visitors increased 31% MoM.

AnaCardio Filings

Explore SEC and related filing metadata, where available.

AnaCardio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AnaCardio's valuation, stock price, and market status.

Is AnaCardio a public or private company?

AnaCardio is a private company.

What is the current stock price of AnaCardio?

AnaCardio is a private company with no public stock price. No recent secondary market data is available.

How much is AnaCardio worth (valuation)?

AnaCardio's valuation is estimated at $1.7M based on funding round data.

Can I buy AnaCardio stock?

AnaCardio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AnaCardio's last funding round?

AnaCardio's most recent funding round was Series A Extension on June 17, 2021.

Who are the main investors in AnaCardio?

Key investors in AnaCardio include Industrifonden, Novo Holdings, Karolinska Development AB, Pureos Bioventures, Sound Bioventures.

Will AnaCardio IPO soon?

No public IPO plans have been announced for AnaCardio.

How can I track AnaCardio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AnaCardio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStockholm
Employee Range21
Year Founded2017
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?